Evidence map›Paper›PMID 34224581›Full record

ArticleTransfusion2021

Undisclosed HIV status and antiretroviral therapy use among South African blood donors.

Karin van den Berg, Marion Vermeulen, Vernon J Louw, Edward L Murphy, Gary Maartens

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. HIV acute infection and long-term undisclosed HIV status among blood donors from the highly endemic Amazonas state, located in the Brazilian Amazon.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Karin van den BergMedical Division, Translational Research Department, South African National Blood Service, Roodepoort, South Africa.
Marion VermeulenDivision of Clinical Haematology, University of the Free State, Bloemfontein, South Africa.ORCID 0000-0003-4383-4526
Vernon J LouwDivision of Clinical Haematology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Edward L MurphyDepartments of Laboratory Medicine and Epidemiology/Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Gary MaartensDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
University of Cape Town · ZAUniversity of California, San Francisco · USUniversity of the Free State · ZA

Funding

Research training in HIV-related transfusion medicine and hematology in South AfricaD43TW010345 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI UTE JENTSCH, EDWARD L MURPHY · 2017 to 2026
$3.0M
FIC NIH HHS 1D43-TW010345FIC NIH HHS D43 TW010345NHLBI NIH HHS HHSN2682011-00001INHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INIH HHSRTI InternationalWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002C
6 · The paper itself

Abstract

backgroundUndisclosed antiretroviral drug (ARV) use among blood donors who tested HIV antibody positive, but RNA negative, was previously described by our group. Undisclosed ARV use represents a risk to blood transfusion safety. We assessed the prevalence of and associations with undisclosed ARV use among HIV-positive donors who donated during 2017. STUDY DESIGN AND

methodsSouth African National Blood Service (SANBS) blood donors are screened by self-administered questionnaire, semi-structured interview, and individual donation nucleic acid amplification testing for HIV. Stored samples from HIV-positive donations were tested for ARV and characterized as recent/longstanding using lag avidity testing.

resultsOf the 1462 HIV-positive donations in 2017, 1250 had plasma availability for testing of which 122 (9.8%) tested positive for ARV. Undisclosed ARV use did not differ by gender (p = .205) or ethnicity (p = .505) but did differ by age category (p < .0001), donor (p < .0001), clinic type (p = .012), home province (p = .01), and recency (p < .0001). Multivariable logistic regression found older age (adjusted odds ratio [aOR] 3.73, 95% confidence interval [CI] 1.98-7.04 for donors >40 compared with those <21), first-time donation (aOR 5.24; 95% CI 2.48-11.11), and donation in a high HIV-prevalence province (aOR 9.10; 95% CI 2.70-30.72) compared with Northern Rural provinces to be independently associated with undisclosed ARV use. DISCUSSION: Almost 1 in 10 HIV-positive blood donors neglected to disclose their HIV status and ARV use. Demographic characteristics of donors with undisclosed ARV use differed from those noted in other study. Underlying motivations for nondisclosure among blood donors remain unclear and may differ from those in other populations with significant undisclosed ARV use.

Indexed as

Blood DonorsBlood SafetyAdultCross-Sectional StudiesDonor SelectionFemaleHIVHIV InfectionsHIV TestingHumansMaleNucleic Acid Amplification TechniquesSouth AfricaYoung Adultanti-retroviral agentsblood donorsdisclosureHIVprevalenceSouth Africa

Identifiers

PMID34224581
PMCPMC8355170
OpenAlexW3180920382

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.